Editor's Note: Green and red arrows refer to intraday stock price movement. NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGESApollo Group ( APOL) estimates, target were raised at Goldman Sachs. Shares now seen reaching $62. Estimates also increased on better than expected enrollment and revenue, Goldman said. Buy rating. Apollo Group estimates changed through 2012 at UBS. Fourth-quarter new starts guidance was worse than expected, UBS said. Maintain Neutral rating and $42 price target. Apollo Group price target raised to $47 at FBR Capital Markets. Company is making progress toward improving student outcomes, FBR said. CareFusion ( CFN) estimates, target lowered at UBS. Shares now seen reaching $31. Estimates also lowered, on lower revenues from respiratory and dispensing, UBS said. Buy rating. Colfax ( CFX) price target was boosted to $30 at Bank of America/Merrill Lynch. Company is leveraged to a turn in the power generation cycle, BofA/Merrill said. Buy rating. Cablevision ( CVC) estimates, target cut at Goldman Sachs. Shares now seen reaching $25. Estimates also lowered on slower growth, Goldman said. Neutral rating. DeVry ( DV) target raised at Citigroup. Price target increased to $64 on attractive fundamentals, diversified revenue mix and low regulatory exposure, Citigroup said. Maintain Buy rating. Forest City ( FCE) estimates changed through 2013 at Goldman Sachs. Near-term growth profile lags peers, Goldman said. Maintain Neutral rating and $18 price target. First Solar ( FSLR) estimates, target raised at UBS. Shares now seen reaching $170. Estimates also increased, on substantial EPS visibility, UBS said. Buy rating. Juniper ( JNPR) estimates, target cut at Barclays. Shares now seen reaching $47. Estimates also lowered on a switching dip and sluggish Japan, Barclays said. Overweight rating. Lam Research ( LRCX) numbers were cut through 2012 at Credit Suisse. Expect lower CapEx spending across the industry, Credit Suisse said. Outperform rating and new $60 price target. Marathon Oil ( MRO) estimates, target cut at UBS. Shares now seen reaching $40. Estimates also lowered to reflect the completion of the downstream spin-off, UBS said. Buy rating.